Compare Marriott International Inc (MAR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Marriott International Inc trades at $355.2 (market cap $92.46B), while State Street SPDR S&P Biotech ETF trades at $157.79. The key difference: Marriott International Inc pays a 0.82% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Marriott International Inc nearer its low. Which is the better fit depends on your goals.
| MAR | XBI | |
|---|---|---|
Market Cap | $92.46B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $402.54 | $164.28 |
52-Week Low | $259.04 | $88.79 |
Enterprise Value | $109.77B | — |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $355.34, up 1.98% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 9.62% net income margin and robust cash flow from operations of $3.21B in 2025, though its valuation remains elevated with a P/E of 36.18. Recent news highlights dividend declarations and AI-driven booking tools, while rising debt levels and Middle East weakness present challenges.
The outlook is mixed; analyst consensus leans bullish with a $387.31 price target, but high valuation and increasing debt-to-asset ratio (58.83% in 2025) cap upside potential. Key risks include regional volatility and competitive pressures, while fee revenue growth and a record pipeline offer opportunities for long-term investors.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
